Calamos Wealth Management’s Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A BSX.PRA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-4,570
| Closed | -$553K | – | 323 |
|
|
2023
Q1 | $553K | Sell |
4,570
-89
| -2% | -$10.8K | 0.04% | 189 |
|
|
2022
Q4 | $535K | Sell |
4,659
-119
| -2% | -$13.7K | 0.04% | 193 |
|
|
2022
Q3 | $484K | Sell |
4,778
-1,270
| -21% | -$129K | 0.04% | 195 |
|
|
2022
Q2 | $614K | Sell |
6,048
-110
| -2% | -$11.2K | 0.05% | 180 |
|
|
2022
Q1 | $717K | Sell |
6,158
-1,044
| -14% | -$122K | 0.05% | 193 |
|
|
2021
Q4 | $826K | Buy |
+7,202
| New | +$826K | 0.06% | 175 |
|
|
2021
Q1 | – | Sell |
-7,797
| Closed | -$854K | – | 302 |
|
|
2020
Q4 | $854K | Buy |
7,797
+252
| +3% | +$27.6K | 0.08% | 159 |
|
|
2020
Q3 | $844K | Sell |
7,545
-183
| -2% | -$20.5K | 0.1% | 141 |
|
|
2020
Q2 | $809K | Buy |
+7,728
| New | +$809K | 0.1% | 127 |
|